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ABSTRACT
NUCKS1 (nuclear casein kinase and cyclin-
dependent kinase substrate 1) is a 27 kD chro-
mosomal, vertebrate-specific protein, for which lim-
ited functional data exist. Here, we demonstrate that
NUCKS1 shares extensive sequence homology with
RAD51AP1 (RAD51 associated protein 1), suggest-
ing that these two proteins are paralogs. Similar to
the phenotypic effects of RAD51AP1 knockdown, we
find that depletion of NUCKS1 in human cells impairs
DNA repair by homologous recombination (HR) and
chromosome stability. Depletion of NUCKS1 also re-
sults in greatly increased cellular sensitivity to mit-
omycin C (MMC), and in increased levels of sponta-
neous and MMC-induced chromatid breaks. NUCKS1
is critical to maintaining wild type HR capacity, and,
as observed for a number of proteins involved in
the HR pathway, functional loss of NUCKS1 leads
to a slow down in DNA replication fork progres-
sion with a concomitant increase in the utilization
of new replication origins. Interestingly, recombinant
NUCKS1 shares the same DNA binding preference
as RAD51AP1, but binds to DNA with reduced affin-
ity when compared to RAD51AP1. Our results show
that NUCKS1 is a chromatin-associated protein with
a role in the DNA damage response and in HR, a DNA
repair pathway critical for tumor suppression.
INTRODUCTION
DNA double-strand breaks (DSBs) are highly toxic and
induced exogenously by ionizing radiation (IR) or inter-
strand crosslinking agents. DSBs also arise from the at-
tack by endogenous reactive oxygen species or from the en-
counter of unrepaired single-strand breaks by DNA repli-
cation forks, and are created during normal development
of the immune system. DSBs elicit a cellular response that
involves the activation of cell cycle checkpoints to facili-
tate double-strand break repair (DSBR), or the activation
of genes involved in promoting apoptosis or senescence.
Defects in the cellular response to DSBs underpin a num-
ber of human diseases, including disorders associated with
cancer predisposition, immune dysfunction, radiosensitiv-
ity, neurodegeneration and premature aging (1–4). When
DSBs occur, cells repair these DNA ends either by homolo-
gous recombination (HR) or by non-homologous end join-
ing (NHEJ), and these two biochemically distinct pathways
are used differently throughout the cell cycle (for review see
(5)).
Previously, we discovered and characterized RAD51-
associated protein 1 (RAD51AP1) with regards to its func-
tion in HR and DSB repair (6–9). Specifically, we showed
that RAD51AP1 interacts with and stimulates the activ-
ity of both RAD51 (6) and DMC1 (7,8), the two con-
served recombinase enzymes that mediate the homologous
DNA pairing reaction during HR. We also showed that
RAD51AP1 is essential for maintaining DNA replication
fork progression (10), as described for other proteins in the
HR pathway (11,12). In addition, and as expected for a ma-
jor player in HR, we (6,10) and others (13,14) showed that
gene-specific knockdown of RAD51AP1 by RNA interfer-
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ence leads to increased cellular sensitivity to DNA damag-
ing agents and to elevated levels of chromatid breaks.
Nuclear casein kinase and cyclin-dependent kinases sub-
strate 1 (NUCKS1) is a nuclear and highly phosphorylated
protein (15–17) which also is acetylated, methylated, ubiq-
uitylated and formylated ((18); http://www.phosphosite.
org/). Only limited functional data exist for NUCKS1,
even though this protein was discovered three decades
ago (19). However, emerging clinical evidence establishes
NUCKS1 as a biomarker for several human diseases, in-
cluding cancer and metabolic syndrome (20–29). Inter-
estingly, NUCKS1 has been picked up in several screens
aimed at identifying changes to the nuclear phosphopro-
teome in response toDNAdamage induction. In 293T cells,
NUCKS1 (i.e. Ser14) was shown to be a substrate of either
the ataxia telangiectasia mutated serine/threonine-protein
kinase (ATM) or the ataxia telangiectasia and Rad3-related
serine/threonine-protein kinase (ATR) following exposure
to ionizing radiation (30), and Ser54 and Ser181 were iden-
tified as ATM-dependent phosphorylation sites in G361
human melanoma cells following treatment with the ra-
diomimetic drug neocarzinostatin (31).
Here, we show that NUCKS1 and RAD51AP1 share ex-
tensive sequence homology throughout and are therefore
paralogs. Since paralogs frequently serve a similar biolog-
ical function, we have tested NUCKS1 for a possible role in
DSBR by HR. We report that, in human cells, targeted in-
activation of NUCKS1 byRNA interference largely pheno-
copies knockdown of RAD51AP1.We show that NUCKS1
is epistatic with both RAD51AP1 and XRCC3, thus reveal-
ing NUCKS1 as a new player in the HR pathway. Knock-
down of NUCKS1 in human cells has no apparent effect on
DNA damage-induced RAD51 focus formation, indicative
of a function of NUCKS1 downstream of RAD51-single-
stranded DNA (ssDNA) nucleoprotein filament formation.
Our findings are the first to demonstrate the biological func-
tion inDSBR forNUCKS1.Our results are of particular in-
terest in the context of several expression-array studies that
report on the altered expression of NUCKS1 mRNA and
protein levels in various types of cancer (20–27). We sug-
gest that elevated levels of NUCKS1may provide a selective
advantage in precancerous cells and during cancer develop-
ment by overcoming the consequences of replication stress,
which leads to DSBs and genomic instability (32,33).
MATERIALS AND METHODS
Cell culture, transfection and siRNAs
HeLa cells and U2OS cells from ATCC were maintained as
recommended. HCA2-hTERT human foreskin fibroblasts
were a kind gift fromDr J. Campisi and were maintained as
described previously (34,35); HCA2-hTERT cells were used
between 52 and 55 cumulative population doublings in this
study. U2OS-DRGFP (i.e. DR-U2OS) cells were a kind gift
from Dr M. Jasin and were maintained as described previ-
ously (36–38).
Small interfering RNAs (siRNAs) were ob-
tained from Qiagen (Valencia, CA). The tar-
get siRNA sequences to knockdown NUCKS1,
XRCC3, RAD51AP1 and PALB2 were as follows: 5´-
AAGAACCTACTTAAGATAGAA-3′ (here: NUCKS1
#1), 5′-AACCGGAAAGCCCGCCAGAAA-3′ (here:
NUCKS1 #2), 5′-AAGAAGGATGATTCTCACTCA-
3′ (here: NUCKS1 #3) for NUCKS1, and 5′-
CAGAATTATTGCTGCAATTAA-3′ for XRCC3, 5′-
AGTCATTTGGATGTCAAGAAA-3′ (here: PALB2#1)
and 5′-CTTAGAAGAGGACCTTATTGT-3′ (here:
PALB2#2) for PALB2, as described (37), and 5′-
AACCTCATATCTCTAATTGCA-3′ for RAD51AP1,
as previously described (9,14). For non-depleting negative
control siRNA, the following target sequence was used:
5′-GATTCGAACGTGTCACGTCAA-3′, as previously
described (39). Where not further specified, a pool of
NUCKS1 siRNAs #1, #2 and #3 was used. BLAST
sequence analyses of the human genome database were
carried out to ensure that all used siRNAs would not
target other gene transcripts. SiRNA forward transfec-
tions were performed using lipofectamine RNAiMAX
(Invitrogen, Carlsbad, CA, USA) on two consecutive days
and according to the instructions of the manufacturer,
combined siRNA and plasmid transfections were car-
ried out using Lipofectamine2000 (Invitrogen, Carlsbad,
CA). SiRNA/lipofectamine RNAiMAX complexes were
formed at a 1:1 ratio, and the concentration of siRNAs
in transfections was 40 nM. Cells were treated with drugs
or ionizing radiation at 72 h after the first transfection,
and the extent of protein knockdown or expression was
assessed by western blot analysis.
Recombination assay and flow cytometry
U2OS-DRGFP (i.e. DR-U2OS) cells have been described
elsewhere (36–38). I-SceI was expressed transiently in
U2OS-DRGFP cells from the pCASCE expression vec-
tor (40) at 0.8 g/150 000 cells and co-transfected with
siRNA using Lipofectamine2000 (Invitrogen, Carlsbad,
CA). Transfected cells were kept in regular growth medium
for 72 h, after which time they were analyzed by flow cy-
tometry to measure the percentage of viable cells expressing
GFP, as previously described (6,41).
Exposure to genotoxic agents and western blot analysis
Exposure of cells to MMC for cell survival assays (Sigma,
St. Louis, MO, USA) occurred in regular growth medium
at 37◦C for 1 h at the concentrations indicated. Cells
were trypsinized, washed twice and re-suspended in fresh
medium, plated and incubated 11 days for colony forma-
tion. Exposure to camptothecin (Sigma, St. Louis, MO) for
camptothecin (CPT)-washout experiments was carried out
at 20 nM in regular growth medium for 24 h. Control cells
were exposed to the equivalent concentrations of DMSO
only. Exposure to hydroxyurea (HU; Sigma, St. Louis,
MO) was carried out at 2 mM in regular growth medium
for 5 h to determine the levels of FANCD2 ubiquityla-
tion. For cell survival assays using CPT or HU, 500–1000
cells were plated in 10-cm dishes, allowed to attach for
24 h before treatment with either CTP or HU for 24 h
and at the concentrations indicated. The medium was re-
moved after 24 h and the monolayers were washed with
PBS once, before incubation in regular growth medium
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for colony formation. Exposure to X-rays and cell syn-
chronization with mimosine occurred as previously de-
scribed (6). Western blot analysis was carried out as pre-
viously described (42). The primary antibodies that were
used are: -RAD51AP1 (NB100-1129; Novus; 1:5000; and
our own -RAD51AP1 antibody, as previously described
in (43)), -XRCC3 (NB100-165; Novus; 1:10 000); -QM
(C-17; Santa Cruz Biotechnology; 1:3000) and -PALB2
(A301-246; Bethyl Lab.; 1:2000), -KU80 (kind gift from
Dr S.M. Yannone; 1:5000), -Tubulin (CP06; EMD Mil-
lipore; 1:3000), -HA (MMS101P; Covance; 1:3000), -
NUCKS1 ((44); 1:10 000), -pRPA32-S4/S8 (A300-245A;
Bethyl Labs; 1:5000), -RPA32 (Ab-3; EMD Millipore;
1:3000), -RAD51 (Ab-1; EMD Millipore; 1:3000), -
RAD51 (H-92; SantaCruzBiotechnology; 1:1000),-ATM
(NB100–104; Novus; 1:1000), -MSH2 (ab52266; Abcam;
1:8000), -FANCD2 (sc-20022; Santa Cruz Biotechnol-
ogy; 1:1000), -H3 (ab1791; Abcam; 1:5000), -pATM-
S1981 (clone 10H11.E12; Millipore; 1:1000), -GAPDH
(3E8AD9; Abcam; 1:1000), -HMGB2 (D1P9V; Cell Sig-
naling; 1:2000). The rabbit pNUCKS1-S54 antibody was
generated to a peptide with the following sequence:
CKNKRRSGKN(pSer)QEDS (GeneScript), and used at
1:6000. HRP-conjugated goat anti-rabbit or goat anti-
mouse IgG (Jackson ImmunoResearch Laboratories, West
Grove, PA; 1:10000) were used as secondary antibodies.
To assess phosphorylatedNUCKS1 (pNUCKS1-S54) by
Western blot analysis, protein extracts were prepared using
perchloric acid (PCA; Sigma, St. Louis, MO) extraction,
essentially as described (19). Briefly, PCA-soluble proteins
were obtained from ∼5 × 106 cells in 1.5 ml 5% ice-cold
PCA using dounce homogenization followed by precipita-
tion of proteins on ice over night in 25% trichloric acid so-
lution (Sigma, St. Louis, MO). After centrifugation, pellets
were washed in 2 ml acetone/ 5 l HCl first, followed by
a second wash in 2 ml acetone only. Pellets were dried and
resuspended in 40 l H2O prior to western blot analysis.
Cell cycle analysis
Briefly, 1 × 106 cells were pelleted, washed in ice-cold PBS,
pelleted and resuspended in 50 l PBS. Cells were fixed by
adding 10 ml of cold 70% ethanol/PBS and kept at 4◦C for
at least 2 days. Fixed cells were pelleted and resuspended in
5 ml 30% ethanol/PBS for 2 min at 4◦C, pelleted and resus-
pended in 1ml 0.05%BSA/PBS for 2 min at 4◦C. Cells were
then resuspended in staining solution (40 g/ml RNase A
and 30 g/ml propidium iodide in PBS; Sigma, St. Louis,
MO) before analysis using a FACS Calibur flow cytometer
(BD Biosciences, San Jose, CA) with 488 nm excitation and
630 nm long pass filter. FlowJo version X (Tree Star, Ash-
land, OR) was used to fit the data for cell cycle analysis.
Analysis of chromosomal aberrations and cell fractionation
HCA2-hTERT human fibroblasts were treated with 50 nM
MMC for 1 h and with colcemid (100 ng/ml; Sigma, St.
Louis, MO) for 4 h prior to fixation. Fixation was carried
out at 24 h post MMC treatment. Cells were detached from
the culture vessel, washed in PBS and allowed to swell in
0.075 M KCl at 37◦C for 10 min. Cells were fixed twice in
methanol:acetic acid (3:1), and dropped on wet slides, air
dried, and stained in 3%Giemsa solution in Sørensen phos-
phate buffer for 10 min. Slides were covered with mounting
media (Vectashield 60; Vector Laboratories, Burlingame,
CA) and analyzed with a Zeiss Axioskop using a 100× lens
with oil and 2000× magnification. For each sample 50–
100 metaphases were analyzed and all visible aberrations
were counted. Gaps were counted as chromatid break (ctb),
when the gap was larger than the chromatid was wide. Cell
fractionation was carried out using the Subcellular Protein
Fractionation Kit (Thermo Scientific, Waltham, MA) and
as described by the manufacturer.
Treatment with PI3K-related kinase inhibitors
To inhibit ATM and/or DNA-PK, cells were incubated
with 5 M KU60019 (Tocris Bioscience, Bristol, UK)
and/or 5MNU7026 (Sigma, St. Louis,MO), respectively,
in regular growth medium 5 h prior to radiation exposure
or MMC treatment. Following treatment, medium was ex-
changed and fresh inhibitor was added for post-treatment
incubation times, as indicated.
Indirect immunofluorescence
Cells, grown on four-well slides, were treated with 8 Gy
X-rays 3 days after the first transfection with siRNA, and
fixed with 4% paraformaldehyde at room temperature for
10 min at the times post radiation exposure, as indicated.
Fixed cells were permeabilized in 0.5% Triton X-100 in PBS
for 5 min, washed in PBS, blocked in 2% BSA for 2 h,
and incubated in blocking solution with primary antibody
to RAD51 (H-92; 1:500; Santa Cruz Biotechnology, Santa
Cruz, CA) at 4◦C overnight. After further washes with PBS,
the cells were incubated for 1 h with AlexaFluor488 goat
anti-rabbit IgG (Invitrogen, Carlsbad, CA) at 4 g/ml in
blocking solution. The slides were mounted in Vectashield
mounting medium containing 1.5 g/ml DAPI.
Microscopy and image analysis
For image capture, Z-stack section images (slices with 0.7
m intervals) were taken using a confocal Zeiss LSM-
710 laser-scanning microscope wit 100×magnification. For
computational analysis, Z-stacks were collapsed down to
the maximum intensity projections. All images were an-
notated with the respective ionizing radiation dose, post-
exposure time and siRNA treatment condition, and regis-
tered with the BioSig (Biological Signature) Imaging Bioin-
formatics Platform, as described (45). Image analysis in-
cluded nuclear segmentation using convexity (46). Each de-
tected nucleus provided the context for foci analysis, follow-
ingmaximumprojection of foci on a nucleus-by-nucleus ba-
sis.
DNA fiber assay
Exponentially growing cells were pulse-labeled with 25 M
CldU (Sigma, St. Louis, MO) and 250 M IdU (Sigma,
St. Louis, MO) for the times specified. Where indicated,
the cells were exposed to 2 mM hydroxyurea (HU; Sigma,
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St. Louis, MO) or 0.5 M topotecan (TPT; Sigma, St.
Louis, MO) for the times specified. Labeled cells were har-
vested and DNA fiber spreads were prepared from 0.5 ×
106 cells/ml, as previously described (47). Slides were in-
cubated in 2.5 M HCl for 90 min and then washed sev-
eral times in PBS, followed by incubation in blocking buffer
(2% BSA, 0.1% Tween in PBS) for 1 h. Acid-treated fiber
spreads were stained with monoclonal rat anti-BrdU anti-
body (1:1000; Oxford Biotechnology Waltham, MA) to de-
tect CldU, followed by monoclonal mouse anti-BrdU an-
tibody (1:15 000; Becton Dickinson, Franklin Lakes, NJ)
to detect IdU. Secondary antibodies were goat anti-rat
AlexaFluor555 and goat anti-mouse AlexaFluor488 (1:500;
Invitrogen, Carlsbad, CA). Primary antibodies were diluted
in blocking buffer. Incubations with rat anti-BrdU antibody
were carried out for 1 h, and incubations with mouse anti-
BrdU antibody were carried out overnight. Secondary an-
tibodies were applied for 1.5 h, and slides were mounted in
Immuno-Fluor mounting medium (MP Biomedicals, Santa
Ana, CA). Fiber tracts were examined using an AxioVert
200Mfluorescencemicroscope (Zeiss, Thornwood, NY) us-
ing a 63× objective. Pictures were taken from randomly se-
lected fields with untangled fibers and analyzed using Im-
ageJ software package. For structure analyses, the frequen-
cies of the different classes of fiber tracks were classified as
follows: red–green (elongating fork), red (stalled or termi-
nated forks), green–red–red–green (first pulse origin) and
green (second pulse origin). For fork speed analyses, the
lengths of CldU and IdU tracks were measured and mi-
crometer values were converted into kilobases. A conver-
sion factor for the length of a labeled track of 1 m =
2.59 kb was used (48). A minimum of 100 individual fibers
was analyzed for each experiment and the means of at least
three independent experiments are presented.
Purification of recombinant proteins
The cDNA for human NUCKS1 was introduced into
the pENTRTM/TEV/D-TOPOR© entry vector (Invitro-
gen, Carlsbad, CA) and an amino-terminal GST-tag
was engineered into pDEST20-NUCKS1. pDEST20-GST-
NUCKS1 was introduced into DH10Bac Escherichia coli
cells for bacmid generation. The bacmids were verified by
PCR and used to transfect SF9 insect cells to generate re-
combinant baculoviruses. After amplification in SF9 cells,
the viruses were used to infect Hi5 insect cells for expression
of GST-NUCKS1 (8 ml virus per 300 ml cells). After a 44-h
incubation at 27◦C, cells were harvested by centrifugation,
frozen in liquid nitrogen, and stored at −80◦C until cell ly-
sis. All purification steps were carried out at 0◦C to 4◦C. To
prepare extract, the frozen cell paste (5 g, from 300 ml cul-
ture) was thawed and suspended in 40 ml of cell breakage
buffer A (25 mM Tris–HCl, pH 7.5, 300 mM KCl, 0.5 mM
EDTA, 1 mM 2-mercaptoethanol, 0.01% Igepal CA-630,
5 mM MgCl2, 2 mM ATP and the following protease in-
hibitors: aprotinin, chymostatin, leupeptin and pepstatin A
at 3 g/ml each, and 1 mM PMSF) for sonication. After
centrifugation (100 000 × g for 90 min), the clarified lysate
was diluted three times with buffer B (25 mMTris–HCl, pH
7.5, 0.5 mM EDTA, 1 mM 2-mercaptoethanol and 0.01%
Igepal CA-630) and loaded on a Q Sepharose column (10
ml total). The column was washed with 30 ml buffer B con-
taining 75 mM KCl before being eluted with 50 ml buffer
B containing 600 mM KCl. The eluate was mixed with 1
ml Glutathione Sepharose 4 Fast Flow resin for 1 h. The
resin was washed sequentially with 10 ml of buffer B con-
taining 600 mM KCl, and then with 10 ml buffer C (25
mM Tris–HCl, pH 7.5, 0.5 mM EDTA, 300 mM KCl, 1
mM 2-mercaptoethanol and 0.01% Igepal CA-630), before
being eluted five times with 1 ml of 20 mM glutathione
in buffer C. The combined eluates were concentrated in a
Centricon-30K concentrator (Amicon), and then fraction-
ated in a Superdex 200 10/300 GL gel filtration column.
The NUCKS1 protein peak fractions were pooled and con-
centrated before being frozen in liquid nitrogen and stored
at−80◦C. RAD51AP1 was purified as previously described
(6). RAD51 was purified as reported earlier (49).
DNA binding assay
32P-labeled DNA substrates (2.5 nM) were mixed with the
indicated amounts of GST-NUCKS1 or GST-RAD51AP1
at 37◦C in 10 l of Buffer D (25mM Tris–HCl, pH7.5,
90 mM KCl, 1 mM dithiothreitol, and 100 g/ml bovine
serum albumin) for 10 min. After the addition of gel
loading buffer (50% glycerol, 20 mM Tris–HCl, pH7.4,
0.5 mM EDTA, 0.05% orange G), the protein–DNA com-
plexes were resolved by 8% native polyacrylamide gel elec-
trophoresis in 1× TAE buffer (40 mM Tris, pH8.0, 20 mM
acetic acid and 1 mM EDTA) at 4◦C. The gels were dried,
and the products were visualized by autoradiography and
quantified using the Molecular Imager FX and Quantity
One 4.6 software (Bio-Rad).
Immobilized template assay to determine chromatin binding
A biotin-labeled 588-bp PCR product was gel purified and
quantified before coupling to streptavidin-coated magnetic
Dynabeads (Invitrogen, Carlsbad, CA), according to the
manufacturer’s instructions. One half of the reaction was
used to assemble chromatin using human histone octamers
(a kind gift from the Core Facility of Protein Expression
and Purification, Department of Biochemistry and Molec-
ular Biology, CSU) by salt deposition, as described previ-
ously (50). Both immobilized DNA and chromatin were
used to assess the binding affinity of purifiedNUCKS1 pro-
tein in comparative assays. Briefly, either DNA or chro-
matin (1 pmol/reaction) and 0.5 or 1 pmol of purified GST-
NUCKS1, (His)6-RAD51AP1 or RAD51 were incubated
in binding buffer (20 mM K2HPO4/KH2PO4, 0.05% NP-
40, 150 mM KCl, 20% glycerol, 0.5 mM EDTA and 2 mM
DTT) with constant shaking at 30◦C for 30 min. Follow-
ing binding, the supernatant was removed, the resin was
washed three times with binding buffer, and the bound pro-
tein was assessed by 10% SDS-PAGE andwestern blot anal-
ysis. We also included as control streptavidin-coated Dyn-
abeads without DNA or chromatin.
Affinity pull-down assays
GST-tagged NUCKS1 (3 g) or GST-tagged RAD51AP1
(5 g) was incubated with human RAD51 (5 g) in 30 l
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buffer B (25 mMTris–HCl at pH 7.5, 10% glycerol, 0.5 mM
EDTA, 0.01% Igepal, 1 mM DTT, 100 mM KCl) on ice
for 30 min, and then 15 l glutathione resin (GE Health-
care) was added. The GST-tagged protein and associated
proteins were captured on the resin by gentle mixing at 4◦C
for 1 h. The resin was then washed three times with buffer B
and treated with 30 l of 2% SDS to elute the proteins. The
supernatant, final wash and SDS-eluted fractions (10 l
each) were analyzed by 10% SDS-PAGE and Coomassie
Blue staining.
Statistical analysis
The statistical analysis was performed using Prism 6
(GraphPad Software, Inc., La Jolla, CA) on the data from
at least three independent experiments, as specified. Un-
less stated otherwise, statistical significance was assessed by
two-tailed unpaired Student’s t-test. P ≤ 0.05 was consid-
ered significant.
RESULTS
NUCKS1 and RAD51AP1 are paralogs
In our attempt to identify more proteins in the RAD51AP1
family, we discovered NUCKS1, a protein with poorly
understood biological function (15–17,23,28,44,51), as a
paralog. The ClustalW sequence alignment of human
RAD51AP1 and NUCKS1 is depicted in Figure 1A.
NUCKS1 shares 28% amino acid sequence identity and
11% sequence similarity with RAD51AP1. We conclude
that NUCKS1 and RAD51AP1 can be considered par-
alogs of each other. Interestingly, human NUCKS1 does
not share the RAD51AP1 C-terminal domain (Figure 1A)
that mediates the interaction with the recombinase enzyme
RAD51 (6,52). According to our analysis, no NUCKS1
homolog from any other vertebrate species possesses this
RAD51-interacting domain (Supplementary Figure S1).
The large gap in theN-terminal region of humanNUCKS1,
as compared to human RAD51AP1, is variable in length
between different species, as can be seen in a comparison
of these two paralogs in Xenopus tropicalis (Figure 1B). Of
note, no function for the N-terminal segment of human
RAD51AP1 that is absent in NUCKS1 has yet been deter-
mined.
Knockdown of NUCKS1 sensitizes human cells to mitomycin
C (MMC)
Being intrigued that NUCKS1 is a paralog of RAD51AP1,
we asked if these two proteins serve similar biological func-
tions. RAD51AP1 is needed for HR-mediated repair of
DNA containing interstrand crosslinks (6,13,14). We there-
fore exposed cells to MMC to induce DNA crosslinks and
testedwhether gene-specific knockdownofNUCKS1would
enhance the cytotoxicity of HeLa cells to such treatment.
Indeed, we found that HeLa cells depleted for NUCKS1
(individually by two different NUCKS1 targeting siRNAs:
N #1 or N #2) show decreased survival after MMC treat-
ment compared to HeLa cells treated with a non-depleting
negative control siRNA (Figure 2A, left panel, and Sup-
plementary Figure S2A). These results suggest that, simi-
lar to RAD51AP1, NUCKS1 is required for the repair of
DNAdamage introduced byMMC,which is known to chal-
lenge the HR pathway (53). The effects of NUCKS1 de-
pletion on MMC-induced cytotoxicity were also observed
when the protein was depleted using a third siRNA (N #3),
and the increase inMMC sensitivity could not be alleviated
by pretreatment with chloroquine (Supplementary Figure
S2B and S2E), which promotes chromatin relaxation (54–
56). These results suggest that the role of NUCKS1 inDNA
crosslink repair is unrelated to its proposed role in relaxing
chromatin during transcriptional processes (28,29).
To test for the epistatic relationship between NUCKS1
and RAD51AP1, we performed MMC cell survival assays
withHeLa cells simultaneously depleted for bothNUCKS1
and RAD51AP1, and compared their sensitivity to MMC
to that of cells singly depleted. In accord with our previ-
ous report (6), we find that knockdown of RAD51AP1 sen-
sitizes HeLa cell ∼2-fold (based on D10 values) to the cy-
totoxic effects of MMC (Figure 2A, middle panel). Inter-
estingly, single knockdown of NUCKS1 or in combination
with RAD51AP1, similarly decreases HeLa cell survival
∼2-fold after MMC treatment (Figure 2A, middle panel,
and Supplementary Figure S2A). These results show that
NUCKS1 and RAD51AP1 are part of the same epistasis
group. In addition, knockdown of NUCKS1 in combina-
tion with knockdown of XRCC3, another important pro-
tein in theHRpathway, also confers no additive or synergis-
tic effect on cell survival afterMMC treatment compared to
single knockdownofNUCKS1 (Figure 2A, right panel, and
Supplementary Figure S2A). Taken together, these results
support the notion that NUCKS1 is epistatic with both
RAD51AP1 and XRCC3, and that this protein likely is a
new factor important for the proper functioning of the HR
pathway.
Knockdown of NUCKS1 sensitizes human cells in S-phase to
X-rays
Next we tested if functional loss of NUCKS1 would affect
the sensitivity of HeLa cells to ionizing radiation. In asyn-
chronous cells, depletion of NUCKS1 only had a very mild
effect on further sensitizingHeLa cells toX-rays (Figure 2B,
left panel). However, NUCKS1 depleted cells that, follow-
ing synchronization with mimosine, were in S-phase during
the radiation exposure showed increased cellular sensitiv-
ity when compared to control cells (Figure 2B, right panel).
These results support the notion that NUCKS1 function
in DNA damage repair following ionizing radiation expo-
sure largely is confined to S-phase cells, as was also reported
for other proteins in the HR pathway (6,14,57). NUCKS1
knockdown also increases cellular sensitivity to the topoi-
somerase I inhibitor camptothecin (CPT; Supplementary
Figure S2C), and to higher concentrations of hydroxyurea
(Supplementary Figure S2D)which leads to depleted dNTP
pools. These results further support the notion that the role
of the NUCKS1 protein in DNA repair is linked to DNA
replication.
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Figure 1. NUCKS1 and RAD51AP1 are paralogs. (A) ClustalW multiple sequence alignment of human NUCKS1 and human RAD51AP1. There is
a 28% amino acid sequence identity (black) and 11% similarity (gray) between both proteins. The C-terminal domain (encompassing the last 25 amino
acids), identified in human RAD51AP1 to facilitate the interaction with RAD51 (52), is underlined. Critical residues within the domain, as identified by
mutational analysis (52), are shown in boxes. (B) ClustalW multiple sequence alignment of NUCKS1 and RAD51AP1 from Xenopus tropicalis. These two
proteins share 29% identity (black) and 11% similarity (grey).
NUCKS1 is phosphorylated in response to X-rays andMMC
treatment
Phospho-Ser54 (pSer54) in NUCKS1 was identified as an
ATM-dependent, DNA damage-induced phosphorylation
site in response to neocarzinostatin treatment (31). To fol-
low up on these findings, we had an antibody made to
the NUCKS1 peptide sequence encompassing pSer54 (i.e.
CKNKRRSGKN(pSer)QEDS). As determined by west-
ern blot analysis, this antibody was specific for detecting
pNUCKS1(S54) in DNA-PK-deficient M059J cells after
exposure to 10 Gy X-rays (Supplementary Figure S2F). In
HeLa cells, phosphorylation of NUCKS1 at Ser54 was de-
pendent on ATM, independent of DNA-PK and detected
as early as 1 h post exposure to 4 Gy X-rays (Figure 2C,
lanes 2–4). The phosphorylation persisted for ∼2 h post-
radiation treatment (Figure 2C, lanes 6–8), and was clearly
diminished by 4 h post exposure (Figure 2C, lane 9). In ac-
cordance with the delayed activation of ATM following in-
terstrand crosslink damage by MMC (58), a clear signal
for pNUCKS1(S54) was detected at 24 h after treatment
with MMC (Figure 2D, lane 7). Treatment with the ATM
inhibitor clearly diminished pNUCKS1(S54), but did not
fully abrogate this phosphorylation (Figure 2D, lane 10).
NUCKS1 depletion promotes chromatid type aberrations
To investigate whether chromosome damage after
NUCKS1 depletion carries the signature of an HR
defect, we tested NUCKS1-depleted cells for their levels
of chromatid breaks (ctbs), both spontaneously and after
the induction of DNA damage by MMC. Chromosome
spreads of NUCKS1 depleted hTERT-immortalized hu-
man HCA2 fibroblasts (HCA2-hTERT; Figure 3C) were
compared to control cells (i.e. transfected with negative
control siRNA) 24 h after a mock or an acute 1-h exposure
to 50 nM MMC. After MMC treatment, a ∼1.5- to 2-fold
increase in the level of induced ctbs was observed for
NUCKS1-depleted cells 24 h after the 1 h MMC treatment
period (Figure 3A and B). In addition, spontaneous
ctbs were slightly elevated in NUCKS1-depleted HCA2-
hTERT cells compared to HCA2-hTERT cells transfected
with negative control siRNA (Figure 3A). After MMC
treatment, we also observed a >2-fold increase in ctbs
in RAD51AP1-depleted HCA2-hTERT cells compared
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Figure 2. NUCKS1 knockdown sensitizes HeLa cells to mitomycin C (MMC) and X-rays, and NUCKS1 is phosphorylated after DNA damage. (A) Sur-
vival curves obtained in control cells (transfected by neg. con. siRNA) or after NUCKS1 depletion following transfection with either NUCKS1 siRNA
N #1 or NUCKS1 siRNA N #2 after treatment with MMC (left panel). NUCKS1- and/or RAD51AP1-depleted HeLa cells show the same increased
cellular sensitivity toMMC treatment compared to control transfected cells (middle panel). NUCKS1- and/or XRCC3-depleted HeLa cells show similarly
increased cellular sensitivity to MMC treatment compared to control transfected cells (right panel). Data points are the means from 3 independent exper-
iments ± 1SD. (B) Cell survival curves obtained after exposure of asynchronous HeLa cells with NUCKS1 or RAD51AP1 depletion to graded doses of
X-rays (left panel). Cell survival curves obtained after exposure of HeLa cells in S-phase and with NUCKS1 or RAD51AP1 depletion to graded doses of
X-rays (right panel). Data are the mean from 3 independent experiments ± SD. (C) Western blots of PCA extracts obtained from HeLa cells to show that
NUCKS1 is phosphorylated in an ATM-dependent manner on serine 54 (S54) after exposure to X-rays. HMGB2 serves as loading control. (D) Western
blots of PCA extracts obtained from HeLa cells to show that NUCKS1 is phosphorylated by ATM on serine 54 (S54) after exposure to MMC. HMGB2
serves as loading control.
to control cells (Figure 3A). This is very consistent with
our previous results for RAD51AP1-depleted HeLa cells
(6). Taken together, these findings reveal that NUCKS1 is
required for the repair of DNA damage in S-phase cells,
suggestive of a role for NUCKS1 in HR-mediated DNA
repair. Next, we asked whether NUCKS1 knockdown
would affect FANCD2 ubiquitylation in response to HU
treatment. Similar to the effects of RAD51AP1 depletion,
we found that the conversion of FANCD2 to FANCD2-Ub
in HeLa cells is not impaired by NUCKS1 depletion
(Figure 3D), suggesting that NUCKS1 does not affect the
early steps of the Fanconi Anemia pathway.
NUCKS1 and RAD51AP1 are equally important for DNA
homology-directed DSB repair
We used the recombinational reporter cell line U2OS-
DRGFP (i.e. DR-U2OS) (36–38) to directly examine the
repair of DSBs induced by I-SceI endonuclease in the con-
text of suppressed expression of NUCKS1. In this system,
gene conversion HR triggered by DSB formation generates
a functional GFP gene, expression of which can be conve-
niently monitored by flow cytometry. Importantly, deple-
tion of NUCKS1 by one of two different siRNAs (N #1 or
N #2) led to a significantly reduced level of gene conversion
(Figure 3E and Supplementary Figure S2G). The level of
impaired homology-mediatedDSBR inNUCKS1-depleted
cells is comparable to that engendered by RAD51AP1
knockdown (Figure 3E; (6)). However, we also found that
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Figure 3. NUCKS1 is required for genome stability and HR repair, is localized to the chromatin fraction and dispensable for FAND2 ubiquitylation.
(A) Chromatid-type aberrations are elevated after NUCKS1 knockdown in HCA2-hTERT fibroblasts. The effects of RAD51AP1 depletion (AP1) are
shown for comparison purposes. **P ≤ 0.01; *P ≤ 0.05. Data are the mean from 3 (neg. con., AP1, and N #1 siRNA) and 2 (N #2 siRNA) independent
experiments± 1 SEM. (B) RepresentativeWestern blots obtained after knockdown of NUCKS1 or RAD51AP1 inHCA2-hTERT cells for the experiments
shown in A. The signal for KU80 serves as a loading control. (C) Representative metaphase spread of NUCKS1-depleted HCA2-hTERT cells obtained
after MMC treatment. Arrow: indicates chromatid break. (D) Western blots to show that the ubiquitylation of FANCD2 is not impaired in HeLa cells
exposed to 2 mM HU and depleted for NUCKS1 by siRNA N #1 or N#2, or depleted for RAD51AP1 (AP1). Extracts from HU-treated cells were
generated 5 h after treatment. The signals forMSH2 and QM serve as loading controls. (E) Homology-directed repair at DR-GFP is reduced in DR-U2OS
cells depleted for NUCKS1 by one of two different siRNAs (N #1 and N #2). **P ≤ 0.01; ***P ≤ 0.001. The effects of RAD51AP1 depletion (AP1) or
of PALB2 depletion by one of two different siRNAs (P #1 and P #2) are shown for comparison purposes. Data are from eight independent experiments
± 1 SD. (F) Representative Western blots obtained for the experiments shown in (E), ensuring similar expression of HA-ISceI in all cell populations. The
signal for KU80 serves as a loading control. (G) Western blots obtained after cell fractionation to show that some NUCKS1 protein is associated with
the chromatin fraction in HeLa cells under spontaneous conditions. The signals for MSH2 and histone H3 serve as loading controls. To obtain NUCKS1
knockdown, a pool of NUCKS1 siRNAs (N #1, #2 and #3) was used. (H) Western blots obtained after cell fractionation to show that NUCKS1 protein
is associated with the chromatin fraction in HeLa cells that were treated with 1 MMMC for 24 h. The signals for MSH2 and histone H3 serve as loading
controls.
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knockdown of PALB2 by one of two different siRNAs elic-
its a more dramatic effect on gene conversion frequency
than depletion of either NUCKS1 or RAD51AP1 (Fig-
ure 3E). This is consistent with the multiple roles of PALB2
in HR (see ‘Discussion’ section). Notably, a comparable
level of transiently expressed I-SceI nuclease was observed
in all cell populations assessed (Figure 3F). Taken together,
these results show that the NUCKS1 protein is involved in
homology-directed DSB repair.
A subpopulation of nuclear NUCKS1 protein is associated
with the chromatin
To assess if NUCKS1 is associated with the chromatin frac-
tion and if its depletion would affect the recruitment of
other HR proteins to chromatin after DNA damage induc-
tion, we fractionated HeLa cells depleted for NUCKS1,
RAD51AP1 or XRCC3 and monitored the levels of sol-
uble nuclear and chromatin-associated ATM, FANCD2,
MSH2,RAD51AP1, RAD51, XRCC3 andNUCKS1with-
out and with MMC treatment by Western blot analysis.
Under spontaneous conditions, the level of soluble nu-
clear RAD51 was slightly diminished in HeLa cells de-
pleted for RAD51AP1 but not diminished in HeLa cells
depleted for NUCKS1 (Figure 3G). Compared to cells
transfected with the control siRNA, the soluble nuclear
level of ATM was increased in NUCKS1-, RAD51AP1-
and in XRCC3-depleted cell populations. NUCKS1 was
associated with the chromatin in control-, RAD51AP1-
and in XRCC3-depleted cells (Figure 3G). Under spon-
taneous conditions, this assay was not sensitive enough
to detect chromatin-bound ATM, FANCD2, RAD51AP1,
RAD51 or XRCC3 (Figure 3G). However, after DNA
damage induction (1 M MMC for 24 h), chromatin-
bound RAD51AP1 and RAD51 were readily detectable in
control-, in NUCKS1- and in XRCC3-depleted cell pop-
ulations (Figure 3H). Compared to control-depleted cells,
NUCKS1-depletion did not affect the levels of recruited
and chromatin-bound RAD51 or RAD51AP1, whereas
RAD51AP1 depletion reproducibly led to reduced amounts
of chromatin-associated RAD51 (Figure 3H). Notably,
NUCKS1 itself was again associated with the chromatin
and this was independent ofRAD51AP1 orXRCC3 knock-
down (Figure 3H). These results show that a small fraction
of the NUCKS1 protein available in the nucleus is associ-
atedwith the chromatin both spontaneously and afterDNA
damage induction.
Depletion of NUCKS1 results in elevated pRPA(S4/S8)
phosphorylation after DNA damage
To further investigate the role of NUCKS1 in DSBR, we
tested if the depletion of NUCKS1 in U2OS cells would af-
fect the level of pRPA(S4/S8) phosphorylation after long-
term exposure to a low concentration of the topoisomerase
I inhibitor CPT (59). To do so, we treated NUCKS1- and
RAD51AP1-depleted U2OS cells and U2OS cells trans-
fected with the control siRNA with 20 nM CPT for 24 h.
We collected cell pellets from unexposed cell populations,
and from cell populations at 0, 24, 48 and 72 h post CPT
treatment and assessed their level of pRPA(S4/S8) by west-
ern blot analysis. Compared to U2OS cells transfected with
the control siRNA, a higher level of phosphorylated RPA
(i.e. pRPA(S4/S8)) was detected in both NUCKS1- and
RAD51AP1-depleted cells immediately (i.e. at 0 h) and at
24 h following CPT wash out (Figure 4A). These findings
could be recapitulated by assessing the fraction of HeLa
cell nuclei with pRPA32(S4/S8) foci using immunocytohis-
tochemistry (Supplementary Figure S2H). By western blot
analysis, elevated pRPAS4/S8was also detected inXRCC3-
depleted U2OS cells compared to control cells at 0 and 24 h
post CPT wash out (Supplementary Figure S2I). Analysis
of the cell cycle distributions at 24 h post CPT washout in
transfectedU2OS cell populations revealed a larger fraction
of cells in G2/M-phase after NUCKS1- and RAD51AP1-
depletion when compared to control cells (Figure 4B).
NUCKS1 is required for efficient recovery from sponta-
neously occurring DNA replication stress
Our results show that NUCKS1 is required for gene conver-
sion (as measured by homology-directed repair at DRGFP)
and affects the replication stress response (as measured by
pRPA(S4/S8) phosphorylation following CPT treatment).
As HR is the preferred repair pathway for DSBs and other
lesions associated with the replication fork in vertebrate
cells (12,60,61), and since it has been shown that a sponta-
neous reduction in replication fork elongation rate and/or
an increased level of origin firing can occur in HR-defective
cells (10,11,62), we tested if NUCKS1 is needed to main-
tain elongation rates during DNA replication. To do so,
we used the DNA fiber technique to assess DNA replica-
tion speed and origin firing by labeling exponentially grow-
ing U2OS cells in two consecutive rounds of 45 min each
with CldU first and then with IdU (Figure 5A). Quantita-
tive analysis of individual replication fibers revealed an al-
most two-fold and statistically significant decrease in DNA
replication speed in NUCKS1-depleted U2OS cells (i.e. by
NUCKS1 siRNA N #2 or N #3) compared to control
cells (i.e. untransfected or transfected with negative con-
trol siRNA) (Figure 5B and Supplementary Figure S3A and
B). These results demonstrate that, similar to RAD51AP1,
BRCA2 and PALB2, NUCKS1 is important for maintain-
ing the proper elongation rate of DNA replication. In ad-
dition, we observed a significant effect on the discontinu-
ity in fork progression toward smaller IdU/CldU length ra-
tios in NUCKS1-depleted cells (Figure 5C), suggesting that
NUCKS1 helps overcome spontaneous DNA damage that
is inhibitory to replication fork progression. Upon further
analysis of these DNA fibers, we noticed a trend toward
a higher number of DNA replication origins in NUCKS1-
depleted cells compared to untransfected cells or to U2OS
cells transfected with the control siRNA. These observa-
tions led us to test if, under unpertubed conditions, in-
creased origin firing occurs in NUCKS1-depleted cells to
compensate for reduced fork progression and discontinuity
in fork progression. Indeed, when compared to control cells,
the combined fractions of first and second pulse origins
were higher inNUCKS1-depleted cells compared to control
cells (Figure 5D). However, this phenotype was not as pro-
nounced as when RAD51AP1 was depleted (Figure 5D).
Importantly, cell cycle progression was unaffected in unper-
turbed NUCKS1-depleted cells, as shown in Figure 4B.
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Figure 4. Wild type levels of both NUCKS1 and RAD51AP1 are required to prevent increased pRPA(S4/S8) levels, indicative of increased replication
stress, after a 24 h low dose camptothecin (CPT) treatment. (A) Western blots to show increased levels of pRPA(S4/S8) in NUCKS1-depleted (upper
panel) and RAD51AP1-depleted (lower panel) U2OS cells, when compared to U2OS cells transfected with negative control siRNA, immediately (0 h)
and at 24 h after a 24-h incubation in 20 nM CPT. (B) Analysis of the cell cycle distributions shows a larger fraction of G2/M-phase cells for NUCKS1-
and RAD51AP1-depleted cells than in control cells transfected with negative control siRNA at 24 h post CPT wash out. Bars represent the means from 3
independent experiments ± 1 SEM. *P ≤ 0.05.
NUCKS1 is required for efficient recovery from inducedDNA
replication stress
Next, we assessed the role of NUCKS1 under conditions
of perturbed DNA replication. To do so, we labeled ex-
ponentially growing cells with CldU for 15 min first, then
incubated the cells in fresh medium containing 2 mM
HU for 30 min, after which time we switched to IdU-
containing fresh medium and incubated for 45 min be-
fore cell lysis (Figure 6A). We determined the fraction of
terminated/stalled forks (i.e. only red-labeled fibers) after
replication fork stalling from short-term HU treatment to
assess the sensitivity of NUCKS1-depleted cells to HU,
and normalized this to the fraction of terminated/stalled
forks under unperturbed conditions for the same cell
population. After HU treatment, the relative fraction
of terminated/stalled forks was significantly increased in
NUCKS1-depleted cells compared to control cells (Fig-
ure 6B and Supplementary Figure S3C). In this assay
and in line with the HU cell survival data (Supplemen-
tary Figure S2D), NUCKS1 depletion shows greater ef-
fects than RAD51AP1 depletion (Figure 6B), suggesting
that NUCKS1 is of greater importance than RAD51AP1
in the recovery from DNA replication fork stalling.
We also determined the elongation rate of restarted repli-
cation forks in NUCKS1-depleted cells by assessing the
progression rate of IdU elongating fibers of CldU-labeled
tracts with and without HU treatment. We found that un-
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Figure 5. NUCKS1 is required for unperturbed and continuous DNA
replication fork progression. (A) The labeling protocol used in this experi-
ment. (B) Knockdown of NUCKS1 impairs DNA elongation rates under
unperturbed conditions. U2OS cells were transfected with one of two dif-
ferent siRNAs targeting NUCKS1 (N #2, N #3), or with negative control
(neg. con.), RAD51AP1 (AP1), or PALB2 siRNA (P #2) for comparison
purposes. Untransfected cells (-) were also assessed. In box plots, boxes en-
compass the 25th–75th percentile, with error bars defining the minima and
maxima. The black horizontal bars within the boxes indicate the means.
The data are from seven independent experiments, except for P #2 siRNA
the data for which are from 3 independent experiments. (C) Knockdown of
NUCKS1 causes discontinuity in replication fork progression. U2OS cells
were transfected as in (B), and elongation rates of red- (CldU) and green-
labeled (IdU) fiber tracts were determined. The data show the distribution
of IdU/CldU length ratios from 400 individual fibers of 7 (neg. con., N #2,
N #3, AP1 siRNA) and 3 (P #2 siRNA) different experiments. Compared
to control cells (neg. con. siRNA), IdU/CdU length ratios ≤ 0.84 are sig-
nificantly shorter for N #2 (P = 0.0023), N #3 (P = <0.0001) and AP1
depletion (P = 0.0207), but not for P #2 depletion (P= 0.1553; one-tailed
Mann Whitney U test). (D) Knockdown of NUCKS1 leads to elevated
levels of first and second pulse replication origins under unperturbed con-
ditions. U2OS cells were transfected as in (B) and first and second pulse
replication origins were determined by quantification of green–red–red–
green and green-only structures, respectively. The data are the means ±
1 SEM of 7 (neg. con., N #2, N #3, AP1 siRNA) and 3 (P #2 siRNA)
independent experiments.
der unperturbed conditions and compared to control cells,
the IdU elongation rate is greatly reduced in NUCKS1-,
RAD51AP1- and PALB2-depleted cells (Figure 6C), as
expected from the aforementioned spontaneously occur-
ring replication stress (see Figure 5). After HU treat-
ment, the IdU elongation rate becomes further diminished
in NUCKS1-depleted cells, very similar to the effects of
RAD51AP1 or PALB2 knockdown (Figure 6C).
Short-term treatment with topotecan (TPT) leads to
the collapse of replication forks and the formation of
replication-associated DSBs, which normally are repaired
via HR (63). Here, we found that, compared to cells
transfected with the control siRNA, NUCKS1- and
RAD51AP1-depleted cells showed similarly increased lev-
els of terminated/collapsed forks after a 30 min exposure to
TPT (Figure 6D and E, and Supplementary Figure S3D),
suggesting that they are equally important for overcom-
ing replication fork collapse in response to TPT treatment.
Next, we determined the elongation rate of restarting repli-
cation forks for both NUCKS1- and RAD51AP1-depleted
cells with TPT treatment. In control-transfected cells, repli-
cation forks after TPT treatment progressed with a simi-
lar elongation rate as in untreated cells (Figure 6F). The
same pattern was observed for RAD51AP1-depleted cells
(Figure 6F). Interestingly, in NUCKS1-depleted cells, af-
ter TPT treatment, replication forks restarted at a signifi-
cantly faster rate (Figure 6F). When assessed for the frac-
tion of second pulse replication origins with and without
TPT treatment, NUCKS1-depleted cells showed a trend to-
ward increased levels of second pulse replication origins,
while RAD51AP1-depleted cells significantly suppressed
firing of second pulse replication origins after TPT treat-
ment (Figure 6G).
DNA and chromatin binding by NUCKS1
We added a GST-tag to the amino terminus of the human
NUCKS1 protein and expressed the tagged protein in Hi5
insect cells. The tagged NUCKS1 protein is soluble, and
a procedure was devised for its purification to near ho-
mogeneity (Supplementary Figure S4A). We used a DNA
mobility shift assay to examine the DNA binding prop-
erties of GST-NUCKS1 to D-loop, dsDNA and ssDNA
(Figure 7A–C, Supplementary Figure S4B and C). GST-
NUCKS1 had no affinity to ssDNA (Figure 7C and Supple-
mentary Figure S4B), but it bound dsDNA and exhibited a
greater preference for the D-loop substrate (Figure 7B and
C, Supplementary Figure S4C). However, when compared
to the DNA-binding properties of RAD51AP1, we found
that RAD51AP1 bound to D-loop and dsDNA with ∼25-
fold and ∼50-fold greater affinity than did NUCKS1, re-
spectively (Figure 7B, compare lanes 2 and 12; Figure 7C,
compare lanes 4 and 10). Next, we used an immobilized
DNA pull-down assay, which allowed us to assemble chro-
matin in vitro using the purified human histone octamer
and a 588 bp biotin-labeled dsDNA fragment bound to
streptavidin-coated magnetic beads. In this assay, we com-
pared binding of NUCKS1 to naked dsDNA vs. chro-
matin (Figure 7D and Supplementary Figure S4D). In-
terestingly, we found that NUCKS1 greatly preferred the
chromatinized substrate over the naked DNA (Figure 7E,
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Figure 6. NUCKS1 is required for the restart of replication forks after fork stalling and fork collapse. (A) Schematic of the DNA labeling protocol used
in (B) and (C). (B) Knockdown of NUCKS1 causes an increase in only red-labeled fibers after HU treatment. U2OS cells were transfected with one of
two different siRNAs for NUCKS1 (N #2, N #3), or with negative control (neg. con.), with RAD51AP1 (AP1) or with PALB2 (P #2) siRNA. The data
are the means ± 1 SEM of three independent experiments. The bar graphs show the fraction of red-labeled fibers after HU treatment, normalized to the
untreated control for each gene-specific knockdown. *P < 0.05; and **P < 0.01; n.s, not significant. (C) Knockdown of NUCKS1 causes a reduction of
DNA elongation rates after HU treatment. U2OS cells were transfected with one of two different siRNAs for NUCKS (N #2, N #3), or with negative
control (neg. con.), RAD51AP1 (AP1) or PALB2 siRNA (P #2). IdU elongation rates were determined by measuring the green (IdU) of both red- and
green-labeled DNA fibers using Image J, and fiber lengths were converted into kb/min, as described (48). IdU elongation rates are presented as the means
± 1 SEM of three independent experiments. ***P < 0.001 (D) Schematic of the DNA labeling protocol used in (E)–(G). (E) Knockdown of NUCKS1
causes an increase in stalled replication forks after topotecan (TPT) treatment. Red-labeled fibers were quantified using Image J. The normalized data (to
untreated cells of each gene-specific knockdown condition) are represented as the means ± 1 SEM of at least three independent experiments. *P < 0.05.
(F) After TPT treatment, NUCKS1-depleted cells show faster elongating IdU tracts compared to unperturbed NUCKS1-depleted cells. IdU elongation
rates were determined by measuring green tracts (IdU) of both red- and green-labeled DNA tracts using ImageJ and tract lengths were converted into
kb/min, as described (48). The data are represented as means ± 1 SEM of three independent experiments. The bar graphs show the IdU elongation rates
for untreated cell populations and after TPT treatment. ***P < 0.001; n.s., not significant. (G) Knockdown of NUCKS1 causes an increase in second
pulse origin firing after TPT treatment. Second pulse origins were determined by quantification of green tracts in both red- and green-labeled DNA tracts
using ImageJ. The data shown are the means ± 1 SEM of three independent experiments. **P < 0.01; n.s., not significant.
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Figure 7. NUCKS1 prefers binding to chromatin over naked DNA, and does not interact with RAD51. (A) Schematics of the DNA substrates used in
(B) and (C). Numbers indicate lengths of DNA fragments in bp. Asterisks denote the position of the 5-prime label. (B) GST-NUCKS1 (0.15–1.2 M)
and GST-RAD51AP1 (0.15–1.2 M, and 0.003–0.03 M for comparison purposes) were incubated with dsDNA and with the D-loop substrate (2.5 nM
each) and analyzed for mobility shifts using 8% polyacrylamide gels (left panels). The results from the quantified mobility shifts were plotted (right panel).
Data points are the means from three independent experiments ± 1SD. See also Supplementary Figure S4C. (C) GST-NUCKS1 (0.15–0.6 M) and GST-
RAD51AP1 (0.15–0.6 M, and 0.006–0.06 M for comparison purposes) were incubated with ssDNA or with dsDNA (2.5 nM each) and analyzed for
mobility shifts using 8% polyacrylamide gels (left panels). The results from the quantified mobility shifts were plotted (right panel). Data points are the
means from 3 independent experiments ± 1SD. See also Supplementary Figure S4B and C. (D) Schematics of the immobilized DNA substrates used (E).
(E) Western blots obtained after the immobilized DNA pull-down assays using either naked DNA (here: DNA (50 nM/reaction)) or chromatinized DNA
(here: chr (50 nM/reaction)) and 10 or 20 nMGST-NUCKS1, as indicated. DNA-boundGST-NUCKS1 (lanes 1 and 2), chromatin-boundGST-NUCKS1
(lanes 3 and 4), bead-only control (lane 5), and unbound GST-NUCKS1 in the supernatants from the reactions in lanes 1–5 (lanes 6–10, respectively). The
signal for histone H3 (here: H3) serves as control for successful chromatinization (lanes 3–4) and shows that histones are not disrupted (no H3 signal in
lanes 8 and 9). (F) SDS-PAGE to show interaction between GST-RAD51AP1 and RAD51 in GST pull-down assay (lane 3). RAD51 does not precipitate
non-specifically (lane 6), and GST-NUCKS1 does not interact with RAD51 (lane 9). S, supernatant containing unbound proteins; W, wash; E, SDS eluate
of the glutathione resin.
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compare lanes 3 and 4 to lanes 1 and 2), whereas both
RAD51AP1 and RAD51 showed no such preference (Sup-
plementary Figure S4E and F). Although NUCKS1 bound
to the D-loop substrate (Figure 7B), it did not stimulate D-
loop formation using either naked or chromatinized DNA
as a donor (Supplementary Figure S5).
NUCKS1 does not interact with RAD51
A pull-down assay was used to examine the ability of GST-
NUCKS1 to interact directly with human RAD51. As ex-
pected from the sequence alignment presented in Figure
1A and in contrast to RAD51AP1 which avidly interacts
with RAD51 (Figure 7F, lane 3), purified NUCKS1 does
not bind RAD51 (Figure 7F, lane 9). Similarly, in extracts
from human cells, we could not detect any interaction of
RAD51 with NUCKS1 in immunoprecipitation reactions
(data not shown). These results indicate that NUCKS1,
unlike RAD51AP1 (6,14,64), does not associate with the
RAD51 recombinase.
DISCUSSION
The NUCKS1 gene consists of seven exons and six introns,
is ubiquitously expressed in all mammalian tissues, and ap-
pears to be a housekeeping gene (44). The NUCKS1 gene
belongs to a group of co-expressed genes located on chro-
mosomal region 1q32.1 that often is amplified in breast can-
cers (23,51,65,66), and other cancers (22,24–26,67,68). Al-
though there is little functional information on NUCKS1,
several studies have suggested a linkage between its high ex-
pression and breast cancer (18,23,29,66,69). NUCKS1 also
was identified as a colorectal cancer prognostic marker and
as a biomarker for recurrence-free survival in cervical squa-
mous cell carcinoma (24,68). However, how elevated levels
of NUCKS1may promote progression towardsmalignancy
is currently unknown.
Based on sequence homology to RAD51AP1, a RAD51-
binding protein intimately involved in homologous recom-
bination DNA repair (HR) as shown by us and the Kanaar
group (6–9,14,43), we have tested and uncovered a role for
NUCKS1 in HR and in maintaining DNA replication in-
tegrity and genome stability. Using a recombinational re-
porter, we have shown that NUCKS1 deletion results in a
significant decrease in gene conversion levels, which is very
similar to the results obtained for either RAD51AP1 or
XRCC3 depletion (this study, (6)). From these results, we
can conclude that NUCKS1 plays a role in HR DNA re-
pair, as does its paralog RAD51AP1. However, the effects
of NUCKS1 or RAD51AP1 knockdown on gene conver-
sion are less severe than what we (this study) and others (37)
have observed for PALB2 knockdown. This may relate to
the multiple roles in HR of PALB2, which functions as an
HR mediator, as a stimulator of the strand invasion step,
and also as a key regulator of the DNA synthesis step after
strand invasion at replication-dependent DSBs (37,70,71).
While recombinant NUCKS1 shows no affinity for ss-
DNA, recombinant RAD51AP1 does (6,14). Albeit with
very different affinities, both NUCKS1 and RAD51AP1
display the same DNA-binding preference for D-loop and
dsDNA. However, while RAD51AP1 stimulates RAD51
activity and D-loop formation in vitro (6,14), NUCKS1
fails to do so. Given our findings that show that NUCKS1
and RAD51 do not interact, the inability of NUCKS1 to
stimulate D-loop formation is not surprising, as the func-
tional synergy of RAD51AP1 with RAD51 is reliant on
complex formation between them (6,14). While, in light of
the many posttranslational modifications of NUCKS1, it
is possible that the NUCKS1 protein that we have isolated
from insect cells lacks the modifications required for its
proper function, it is also very possible that the functions
of NUCKS1 and RAD51AP1 in HR have diverged. How-
ever, as for RAD51AP1 (6,10,14), we find that NUCKS1
is not required for the formation of RAD51 foci follow-
ing DNA damage induction by ionizing radiation (Supple-
mentary Figure S6A and B), suggesting that NUCKS1, like
RAD51AP1, functions downstream of RAD51-ssDNA nu-
cleoprotein filament formation in HR. Notably, as assessed
by cell fractionation assays, NUCKS1 depletion also does
not affect the levels of RAD51 recruited to the chromatin
after MMC treatment, while RAD51AP1 ablation exerts a
small but consistent effect.
Our results further suggest that NUCKS1 behaves like
other proteins in the HR pathway, including RAD51AP1,
in affecting the tolerance of cells to replication stress. Since
many DNA-damaging agents, including those that are used
in cancer therapy, act by inducing replication stress, it is im-
portant to better understand the complexity of the replica-
tion stress response (72). This is particularly useful in an-
ticipation of the development of new cancer treatment reg-
imens and with respect to the fact that a close but poorly
understood link exists between elevated NUCKS1 expres-
sion and cancer development processes (23,24,26,51,65,73).
Our results show that NUCKS1 is important for the pro-
gression of DNA replication forks. Under conditions of un-
perturbed DNA replication, we have found that the elon-
gation speed of individual replication forks is greatly re-
duced upon NUCKS1 depletion. Concomitantly, we have
observed a trend towards increased replication origin fir-
ing in NUCKS1-depleted cells without any notable effect
on cell cycle progression, as reported previously for other
factors that globally reduce replication fork speeds, includ-
ing RAD51AP1 (10,74–76). Short-term treatment with HU
leads to the depletion of the pool of dNTPs and to repli-
cation fork stalling. HU-induced replication fork stalling
can be more deleterious to cells when coupled with a HR
deficiency (10,77,78), and this also is what we have ob-
served here for cells with NUCKS1 knockdown. In the
same manner, the speed at which restarted forks progress
becomes shortened significantly in NUCKS1-depleted cells
after HU treatment. Taken together, our results show that
HR-defective, NUCKS1-depleted U2OS cells are sensitive
to replication stress under unperturbed conditions and also
after short-term HU treatment stemming from an impaired
ability to overcome replication fork stalling. Of note, we
have found that cells depleted for PALB2 are greatly im-
paired in their ability to restart stalled replication forks as
well (Figure 6B), a finding that is in agreement with a pre-
vious report (11). It is also interesting to note that, despite
the fact that fork stalling in response to HU treatment is
higher after NUCKS1 knockdown than after RAD51AP1
knockdown, the rates of restarted forks are very similar
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forNUCKS1- andRAD51AP1-depleted cells. These results
suggest that NUCKS1 and RAD51AP1 play an equally im-
portant role in the resumption of replication after short-
term HU treatment.
Treatment of cells with the topoisomerase I (Topo I)
covalent poison TPT results in the formation of a co-
valent DNA–Topo I conjugate and a single-strand break
(SSB). Collision between a DNA polymerase with this le-
sion leads to replication fork collapse and DSB formation.
HR repair is thus critically important for mitigating TPT-
induced replication stress. We have shown that NUCKS1-
and RAD51AP1-depleted cells are equally sensitive to the
effects of TPT treatment.However,NUCKS1-depleted cells
are able to overcome TPT treatment more promptly, and
while second pulse origin firing (after TPT treatment) is still
reduced inRAD51AP1-depleted cells, enhanced firing is ac-
tually observed in NUCKS1-depleted cells. We speculate
that RAD51-mediated fork reversal (79), which has been
described to occur in response to topoisomerase poisoning
(80), may occur to some extent in NUCKS1-depleted cells,
but may be more severely compromised under RAD51AP1
deficiency.
As measured by the increased accumulation of
pRPA(S4/S8) after long-term, low dose CPT treat-
ment upon protein depletion, we further substantiated
our findings that NUCKS1 is required to alleviate repli-
cation stress. In the same manner, both RAD51AP1 and
XRCC3, established HR factors, are required to limit
pRPA(S4/S8) accumulation after CPT treatment. Of note,
S4/S8 in RPA2 are phosphorylated under conditions that
cause DSBs (81). While elevated levels of pRPAS4/S8 are
indicative of ongoing replication stress (82), our analyses
of the corresponding cell cycle profiles also revealed an
extended G2/M checkpoint arrest after CPT treatment
in both NUCKS1- and RAD51AP1-depleted cells. It is
important to note that increased pRPA(S4/S8) has been
shown to contribute to G2/M checkpoint arrest and to
HR suppression (83), such that mutagenesis of S4 and S8
to alanines causes increased mitotic entry with enhanced
RAD51 foci formation and HR repair (83). Taken together,
our pRPA(S4/S8) data further support a defect in HR
repair of DSBs stemming from replication stress in cells
with reduced expression of NUCKS1.
Off-target RAD51 depletion was noted as a major source
of identified false positive genes in HR (84). However, for
all NUCKS1 siRNAs tested here, we clearly can exclude
such an effect on RAD51. Nonetheless, we have been un-
able to rescue the increase in cytotoxicity and the decrease
in homology-mediated repair of NUCKS1-depleted cells
by overexpression of the siRNA-resistant NUCKS1 cDNA
from ectopic promoters. We attribute this observation to
the fact that NUCKS1, in addition to the phosphorylation
at S54 induced by ionizing radiation or MMC exposure as
shownhere, is heavily post-translationallymodified and sus-
pect, that ectopically expressed NUCKS1may lack some of
the modifications that are critical for its homeostasis and
function in cells. Of note, the inability to rescue has been
observed before for DSBR defects associated with MSH2
or MLH1 deficiency (85).
In summary, we have provided substantial evidence for
a role of the NUCKS1 protein in the HR pathway. We
surmise that, as has been proposed for other genes in the
DNA damage response (32,33), elevated levels of NUCKS1
may provide a selective growth advantage for premalignant
cells that experience induced replication stress andmay con-
tribute towards the development of malignancy. The mech-
anism by whichNUCKS1 influences HR and attenuates the
replication stress response remains to be determined. Al-
though clearly a RAD51AP1 paralog, NUCKS1 may have
gained different functions. For example, a recent report im-
plicates a role for NUCKS1 in transcriptional regulation
and that it regulates the DNA structure to allowRNApoly-
merase II access to the promoter of genes involved in the
insulin-signaling and other pathways (28). Interestingly, for
both BRCA1 and PALB2, two important HR factors, a
role in transcriptional regulation, independent of their func-
tion in HR, has also been described (86,87). Although we
have entertained a comparable role for NUCKS1 in affect-
ing the expression of genes involved in DSB repair, our
investigation of a large number of candidate genes have
shown no role of NUCKS1 in the regulation of their expres-
sion. In addition, based on our experiments using chloro-
quine to force chromatin relaxation, we can detect no role
for NUCKS1 in DNA repair related to major effects on
the overall chromatin structure, unlike what was observed
for the early HR factor RNF20 (56). It is possible, how-
ever, thatNUCKS1, which appears to function downstream
of RAD51 filament formation, is involved in HR by very
locally regulating the accessibility of DNA repair factors
to chromatin, and our results from the immobilized DNA
pull-down assay using chromatin as a substrate support
such a premise. In addition, it is also possible thatNUCKS1
is a multi-functional protein, with its potentially diverse bi-
ological tasks being governed by its abundant and highly
dynamic post-translational modifications.
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